Additionally, the data of ADAURA trial report that adjuvant EGFR-TKI (osimertinib) significantly improves in DFS in patients with stage IB/II/IIIA EGFR-mutant NSCLC [96]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.